The goal of this observational study is to to assess of treatment Outcomes of Aquired Aplastic Anemia in children
Children aged 1-18 years diagnosed with acquired aplastic anemia, as confirmed by bone marrow examination and fulfilling diagnostic criteria (e.g., bone marrow cellularity <25% and at least two of the following: absolute neutrophil count <500/μL, platelet count <20,000/μL, absolute reticulocyte count <60,000/μL)123.
The bone marrow biopsy should be compitable with diagnosis
Diagnosed and/or treated at Assiut University Children's Hospital between Agust 2023 and Augst 2026.
Patients with complete medical records, including diagnostic, laboratory, and treatment data
Patients with inherited bone marrow failure syndromes (e.g., Fanconi anemia, dyskeratosis congenita) as confirmed by genetic testing or family history21.
Patients with incomplete or missing essential data in their medical records.
Patients diagnosed outside the specified study period or managed primarily at other institutions.
Patinets with neoplastic or granulomatous disease involving the bone marrow, systemic lupus erythematosus, AIDS, hypersplenism or other conditions associated with pancytopenia such as myelodysplastic syndrome,and paroxysmal nocturnal hemoglobinuria.
Children aged 1-18 years diagnosed with acquired aplastic anemia
Cohort
Other
Not listed
To evaluate the treatment outcomes of children diagnosed with aplastic anemia.
To assess response rates to various treatment modalities, including: oImmunosuppressive therapy (IST) oHematopoietic stem cell transplantation (HSCT) oSupportive care only
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
